1. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55
2. Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020;55
3. Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F. Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020;8:695.
4. Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian centre study on tocilizumab versus standard of care. J Clin Virol. 2020
5. Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36–42.
6. Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017 Jul; 13(9): 1972–1988.
7. Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020
8. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19
9. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front Immunol. 2020 Jul 10;11:1708.
10. Persatuan Dokter Paru Indonesia, Persatuan Dokter Spesialis Penyakit Dalam Indonesia, Persatuan Dokter Spesialis kardiovaskular Indonesia, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia, Ikatan dokter Anak Indonesia. Pedoman tatalaksana COVID-19. Edisi 3. 2020. Available from: https://www.papdi.or.id/pdfs/983/Buku%20Pedoman%20Tatalaksana%20COVID-19%205OP%20Edisi%203%202020.pdf
11. National Health Institute. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021 Available from: https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/
12. Gupta S, Wang W, Hayek SS. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern Med. 2021;181(1):41-51. doi:10.1001/jamainternmed.2020.6252
13. RECOVERY, Horby PW, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, Thomas K, jeebun V et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. The Lancet. 2021; 397(10285): 1637-1645
14. Lan S, Lai C, Huang H, Chang S, Lu L, Hsueh P. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020 ; 56(3): 106103.
15. Conti V, Corbi G, Sellitto, Sabbatino F, Maci C, Bertini N, de Bellis E, et al. Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis. J Pers Med. 2021 Jul; 11(7): 628.